Trial · NCT06736353
Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study
NCT06736353, Completed, Uppsala University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study. Trials, record NCT06736353. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06736353
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Classic Secondary Prevention in Type 2 MI: A Target Trial Emulation Study
- NCT number
- NCT06736353
- Status
- Completed
- Enrollment
- 14,000 participants, actual
- Lead sponsor
- Uppsala University
- Conditions
- Myocardial Infarction Type 2
- Interventions
Beta Blocker Therapy or No Therapy (Control), RAAS blocker Therapy or No therapy (Control), Statin Therapy or No Therapy (Control), Single Antiplatelet Therapy or No Therapy (Control), Dual Antiplatelet Therapy or No Therapy (Control)
- First posted
- 2024-12-16
- Last updated
- 2025-03-19
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite | From enrollment (hospital discharge after type 2 MI) until Composite endpoint, Loss to follow-up or End of follow up (date of data collection: 05-May-2022) | Composite endpoint: All-cause mortality, readmission for MI, stroke or heart failure |
| Secondary | All-cause mortality | From enrollment (hospital discharge after type 2 MI) until Death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022) | Death from any cause |
| Secondary | Cardiovascular mortality | From enrollment (hospital discharge after type 2 MI) until Cardiovascular death, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Death from cardiovascular disease |
| Secondary | Readmission for MI | From enrollment (hospital discharge after type 2 MI) until Readmission for MI, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Readmission for myocardial infarction |
| Secondary | Readmission for stroke | From enrollment (hospital discharge after type 2 MI) until Readmission for Stroke, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Readmission for stroke |
| Secondary | Readmission for heart failure | From enrollment (hospital discharge after type 2 MI) until Readmission for Heart failure, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Readmission for heart failure |
| Other | Readmission for Asthma or COPD | From enrollment (hospital discharge after type 2 MI) until Readmission for Asthma/COPD, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Safety outcome in Beta blocker target trial emulation. Readmission for Asthma or Chronic Obstructive Pulmonary Disease. Only if main diagnosis. |
| Other | Readmission for Acute renal failure | From enrollment (hospital discharge after type 2 MI) until Readmission for Acute renal failure, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Safety outcome in RAAS blocker target trial emulation. Readmission for Acute renal failure. |
| Other | Readmission for bleeding | From enrollment (hospital discharge after type 2 MI) until Readmission for Bleeding, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Safety outcome in SAPT and DAPT target trial emulations. Readmission for bleeding. |
| Other | Readmission for Pneumonia | From enrollment (hospital discharge after type 2 MI) until Readmission for bacterial pneumonia, Loss to follow-up or End of follow up (date of data collection: 05-May-2022). Competing risk methodology applied. | Negative control outcome in all target trial emulations. Readmission for bacterial pneumonia. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06736353
GET https://conductscience.org/api/trials/v1/NCT06736353/registered